InVivo Therapeutics (Cambridge, Massachusetts) reported the reopening of subject enrollment for the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury.

Aethlon Medical (San Diego) reported that the FDA has approved a clinical protocol to treat Ebola-infected individuals in the U.S. with the Aethlon Hemopurifier. In the treatment of viral pathogens, the Hemopurifier is a first-in-class bio-filtration device designed for the single-use removal of viruses and shed glycoproteins from the circulatory system of infected individuals.

Medtronic (Minneapolis) reported that the FDA has approved the company's IN.PACT Admiral drug-coated balloon (DCB) for the interventional treatment of peripheral artery disease (PAD) in the upper leg, a serious and common cardiovascular condition that causes pain in the legs and is known to be associated with a four- to five-fold increase in risk for heart attack and stroke.